Therapeutic efficacy and pharmacokinetic
โ
Joachim Z. Fuks; Merrill J. Egorin; Joseph Aisner; David A. Echo; Stanley Ostrow
๐
Article
๐
1983
๐
Springer
๐
English
โ 480 KB
Twenty-nine patients with non-small cell lung cancer refractory to prior therapy were treated with either vindesine (VDS) alone (3 mg/m2 every week) or the combination of VDS plus cisplatin (DDP) (100 mg/m2 every 28 days). Serial blood and urine samples were collected to assess the pharmacokinetics